Citi Pharma Ltd. has received authorization from the Competition Commission of Pakistan (CCP) for the acquisition of 100% shareholding in Pakheim International Pharma (Private) Limited. This approval indicates that the transaction does not raise any competition concerns.
- CCP authorized the acquisition on October 9, 2026, under Case No. 1614/Merger-CCP/2026.
- The acquisition will proceed as per the Share Purchase Agreement dated May 6, 2026.
- Citi Pharma will disclose further details upon completion of relevant transaction milestones.